FDA Grants Fast Track Designation For Prevail’s Parkinson’s Treatment

FDA Grants Fast Track Designation For Prevail’s Parkinson’s Treatment
Prevail Therapeutics (NASDAQ: PRVL) shares are trading higher after the company received FDA fast track designation for PR001 for the treatment of Parkinson's disease patients with a GBA1 mutation. ... read more
Source: Bing NewsPublished on 2019-07-08